161 The trials involved adult participants with T2DM aged 18 to 75, conducted across 42 research and medical centers in the United States
Ive also done a video about Takesumi, if you prefer that format
Of note, almost half of patients treated with GLP-1-RAs also had pre-existing migraine as comorbidity (26.7% in the UCWM group), which could predispose them to worse (rather than better) headache outcomes [31], providing additional evidence of a favorable effect of GLP-1-RAs on headache improvement
La expectativa es ver una reduccin significativa de los gastos en salud, dijo Moore
[1] [2] Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist with similar clinical effects
1 1 2 Weight loss outcomes by engagement quartile *Based on a January 2026 analysis of 14,210 Noom GLP-1 Rx program members who joined between December 2024 and February 2025 and logged weight during a measurement week (4, 8, 16, 40 weeks) Total months persisted by engagement quartile *Based on a January 2026 analysis of 30,239 Noom GLP-1 Rx program members who joined between December 2024 and February 2025 Frequently Asked Questions Weight Loss and Engagement: January 2026 analysis of 14,203 Noom GLP-1 Rx Program members who started a GLP-1Rx plan between December 2024 and February 2025 and logged weight during a measurement week (4, 8, 16, 40 weeks)
